SHENZEN, China, March 27 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS) www.htdsmedical.com Today after the market closed the company announced the clinical trial protocol for their MMR Vaccine is under preparation, and is expected to be approved by the end of the second quarter 2009.
The MMR Vaccine is a mixture of three live attenuated viruses administered via injection for immunization against measles, mumps, and rubella (also called German measles). It is generally administered to children around the age of one year, with a second dose before starting school (i.e. age 4/5).
Prior to the widespread use of a vaccine against measles, its incidence was so high that infection was felt to be inevitable. Today, it is widely used around the world, and since introduction of its earliest versions in the 1970s, more than 500 million doses have been administered in over 60 countries. The incidence rate has fallen to a low of less than 1% of people under the age of 30 in countries with routine childhood vaccination.
The company will provide further details as they become available.
Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.
CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, readers should contact the company directly at corporate@htdsmedical.com
CONTACT: For medical and scientific dialogue inquiry only, please contact
medicalinfo@htdsmedical.com; For any corporate matters, readers should
contact the company directly at corporate@htdsmedical.com
